ALINT Stock Overview
Provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
IntegraGen SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.45 |
| 52 Week High | €1.05 |
| 52 Week Low | €0.45 |
| Beta | 0.19 |
| 11 Month Change | -20.00% |
| 3 Month Change | -28.25% |
| 1 Year Change | -56.95% |
| 33 Year Change | -58.15% |
| 5 Year Change | -52.92% |
| Change since IPO | -95.02% |
Recent News & Updates
Lacklustre Performance Is Driving IntegraGen SA's (EPA:ALINT) Low P/S
Aug 28
There's No Escaping IntegraGen SA's (EPA:ALINT) Muted Revenues
Feb 17Shareholder Returns
| ALINT | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -3.8% | -7.7% | -0.3% |
| 1Y | -57.0% | -26.4% | -3.5% |
Return vs Industry: ALINT underperformed the French Biotechs industry which returned -26.4% over the past year.
Return vs Market: ALINT underperformed the French Market which returned -3.5% over the past year.
Price Volatility
| ALINT volatility | |
|---|---|
| ALINT Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALINT's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALINT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 55 | Bernard Courtieu | integragen.com |
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company’s genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts.
IntegraGen SA Fundamentals Summary
| ALINT fundamental statistics | |
|---|---|
| Market cap | €2.99m |
| Earnings (TTM) | -€171.40k |
| Revenue (TTM) | €12.60m |
0.2x
P/S Ratio-17.5x
P/E RatioIs ALINT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALINT income statement (TTM) | |
|---|---|
| Revenue | €12.60m |
| Cost of Revenue | €7.37m |
| Gross Profit | €5.23m |
| Other Expenses | €5.41m |
| Earnings | -€171.40k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.026 |
| Gross Margin | 41.54% |
| Net Profit Margin | -1.36% |
| Debt/Equity Ratio | 55.9% |
How did ALINT perform over the long term?
See historical performance and comparison